Physician profile
Preethi John
NPI 1841553518
$6,663.16
in general payments reported to CMS, 2019-2025
26 companies · $2,998 in 2025
The $2,998 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.92 · 2020: $75.66 · 2021: $48.23 · 2022: $281 · 2023: $1,135 · 2024: $2,085 · 2025: $2,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,592 · Long Term Medical Supply Or Device Loan: $1,850 · Consulting Fee: $1,750 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.23 |
| Long Term Medical Supply Or Device Loan | $1,849.63 |
| Consulting Fee | $1,750.00 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,894.71 | 2022-2025 | |
| Lilly USA, LLC | $1,767.04 | 2023-2025 | Verzenio |
| Daiichi Sankyo INC. | $992.03 | 2022-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $543.93 | 2023-2025 | Enhertu, Imjudo, Imfinzi |
| Tempus Ai, INC | $198.48 | 2024-2025 | Xt Cdx |
| Stemline Therapeutics INC. | $160.07 | 2023-2025 | Orserdu |
| Merck Sharp & Dohme LLC | $144.15 | 2019-2024 | Keytruda |
| Gilead Sciences, INC. | $139.39 | 2021-2025 | Trodelvy |
| Tactile Systems Technology INC | $118.46 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Abbvie INC. | $111.90 | 2024-2025 | |
| Pfizer INC. | $90.85 | 2023-2024 | |
| Amgen INC. | $80.45 | 2019-2020 | |
| Genentech USA, INC. | $80.27 | 2023-2024 | Phesgo, Itovebi |
| Regeneron Healthcare Solutions, INC. | $61.14 | 2024-2025 | Libtayo |
| Incyte Corporation | $58.34 | 2021-2024 | Jakafi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $46.80 | 2021-2024 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $36.47 | 2022-2023 | Imbruvica, Epkinly |
| Janssen Biotech, INC. | $22.81 | 2023 | Imbruvica |
| Servier Pharmaceuticals LLC | $22.14 | 2024 | |
| Adc Therapeutics America, INC. | $22.02 | 2024 | |
| Blueprint Medicines Corporation | $20.59 | 2023 | Ayvakit |
| Jazz Pharmaceuticals INC. | $20.48 | 2023 | Vyxeos |
| Genmab U.S., INC. | $15.37 | 2024 | Epkinly |
| Rigel Pharmaceuticals, INC. | $15.27 | 2024 | Rezlidhia, Tavalisse |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preethi John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.